Modulated Inflammation by Injection of High-Mobility Group Box 1 Recovers Post-Infarction Chronically Failing Heart
Authors:
- Satsuki FukushimaSFSatsuki Fukushima
- Kenichi YamaharaKYKenichi Yamahara
- Kenta YashiroKYKenta Yashiro
- Yasunori ShintaniYSYasunori Shintani
- Steven R. CoppenSCSteven R. Coppen
- Husein K. SalemHSHusein K. Salem
- Scott W. BrouiletteSBScott W. Brouilette
- Magdi H. YacoubMYMagdi H. Yacoub
- Ken SuzukiKSKen Suzuki
- 30 September 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 118 (14_suppl_1) , S106-14
Abstract
Background— Inflammation plays an important role in the progress of adverse ventricular remodeling after myocardial infarction. High-mobility group box 1 (HMGB1) is a nuclear protein, which has recently been uncovered to also act as a modifier of inflammation when released. We hypothesized that HMGB1 injection could preferentially modulate local myocardial inflammation, attenuate ventricular remodeling, and subsequently improve cardiac performance of postinfarction chronic heart failure. Methods and Results— Three weeks after left coronary artery ligation, HMGB1 (2.5 μg) or PBS was intramyocardially injected into rat hearts. At 28 days after injection, left ventricular ejection fraction was significantly improved after HMGB1 injection compared to PBS (39.3±1.4 versus 33.3±1.8%; P + inflammatory cells, two thirds of which were OX62 + dendritic cells, in the peri-infarct area was significantly attenuated by HMGB1 injection. Dramatic changes in the expression of major proinflammatory cytokines were not detected by microarray or RT-PCR. Adverse ventricular remodeling including cardiomyocyte hypertrophy (cardiomyocyte cross-sectional area; 439±7 versus 458±6 μm 2 ; P P Conclusion— HMGB1 injection modulated the local inflammation in the postinfarction chronically failing myocardium, particularly via reducing the accumulation of dendritic cells. This modulated inflammation resulted in attenuated fibrosis and cardiomyocyte hypertrophy, which thereby improved global cardiac function. These data suggest that HMGB1 may be valuable for the chronic heart failure treatment.Keywords
This publication has 27 references indexed in Scilit:
- Direct Intramyocardial But Not Intracoronary Injection of Bone Marrow Cells Induces Ventricular Arrhythmias in a Rat Chronic Ischemic Heart Failure ModelCirculation, 2007
- High-Mobility Group Box 1 Activates Integrin-Dependent Homing of Endothelial Progenitor CellsCirculation Research, 2007
- A novel pathway of HMGB1‐mediated inflammatory cell recruitment that requires Mac‐1‐integrinThe EMBO Journal, 2007
- Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injuryJournal of Leukocyte Biology, 2006
- HSP60 induces self‐tolerance to repeated HSP60 stimulation and cross‐tolerance to other pro‐inflammatory stimuliEuropean Journal of Immunology, 2004
- Mini‐review: The nuclear protein HMGB1 as a proinflammatory mediatorEuropean Journal of Immunology, 2004
- MEK1-ERK2 Signaling Pathway Protects Myocardium From Ischemic Injury In VivoCirculation, 2004
- Targeted Anticytokine Therapy in Patients With Chronic Heart FailureCirculation, 2004
- Release of chromatin protein HMGB1 by necrotic cells triggers inflammationNature, 2002
- Kinetics of tumor necrosis factor α in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor α in acute myocardial infarctionAmerican Heart Journal, 1999